ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York
IPA(NASDAQ:IPA) AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8th through September 10th, 2025. Dr. Jennifer Bath, President CEO of IPA, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Event Details: Conference: 27th Annual H.C. Wainwright Global Investment Conference D
ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation
IPAAUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery today announced the next milestone in its universal dengue vaccine program. Building on its June announcements confirming the discovery and validation of a uniquely conserved dengue epitope using its LENSai™ platform powered by patented HYFT® technology, the Company has updated that they are now advancing to
AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.
IPAWASHINGTON & NORWICH, Conn.--(BUSINESS WIRE)--Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced that its portfolio company AVS Bio, a leading global provider of critical inputs and services for the bioprocessing and biologics industries, acquired ImmunoPrecise Antibodies (Europe) B.V. (“IPA Europe” or the “Company”). IPA Europe is a carve-out of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a
ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation
IPAAUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery, today announced the successful sale of its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V. (“IPA Europe”), to AVS Bio for a total enterprise value of $12 million USD. AVS Bio, a portfolio company of Arlington Capital Partners, is a leading global provider of critical inputs and services
ImmunoPrecise Antibodies Announces In Vitro Results Demonstrating Its GLP-1RA Peptide Sequences Achieve Comparable Or Superior Receptor Activation To Semaglutide
IPAAI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
IPAAUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (AI)-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior receptor activation to Semaglutide, a benchmark GLP-1 therapy and one of the most commercially successful drugs in the world. The in vitro analysis was conducted by an independ
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
IPAAUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (AI)-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior receptor activation to Semaglutide, a benchmark GLP-1 therapy and one of the most commercially successful drugs in the world. The in vitro analysis was conducted by an independ
ImmunoPrecise's AI-Powered LENSai Platform, Driven By Patented HYFT Technology, Identifies A Highly Conserved Multi-Factorial Epitope Across All Four Dengue Virus Serotypes
IPAImmunoPrecise Announces Benchmarking Results For LENSai Epitope Mapping
IPAHC Wainwright & Co. Reiterates Buy on ImmunoPrecise Antibodies, Maintains $5 Price Target
IPAImmunoPrecise Antibodies Announces Its Support For FDA's Recent Decision To Phase Out Animal Testing Requirements For Monoclonal Antibodies And Other Pharmaceutical Products
IPABenchmark Reiterates Speculative Buy on ImmunoPrecise Antibodies, Maintains $3 Price Target
IPAHC Wainwright & Co. Maintains Buy on ImmunoPrecise Antibodies, Lowers Price Target to $5
IPAImmunoPrecise Antibodies Q3 2025 GAAP EPS C$(0.66) May Not Be Comparable To C$(0.08) Estimate, Sales C$6.15M Miss C$6.58M Estimate
IPAA Look Ahead: ImmunoPrecise Antibodies's Earnings Forecast
IPAHC Wainwright & Co. Reiterates Buy on ImmunoPrecise Antibodies, Maintains $7 Price Target
IPAWhat's Going On With ImmunoPrecise Stock Thursday?
IPAImmunoPrecise announced a partnership with a biotechnology giant to develop ADCs and bispecific antibodies for the treatment of cancer.
Immunoprecise Antibodies Announced A Strategic Partnership To Advance The Discovery And Development Of Antibody-drug Conjugates And Bispecific Antibodies For Cancer Valued At $8M-$10M
IPAIPA Announces Collaboration With RIBOPRO For Antibody Discovery
IPAImmunoPrecise Antibodies Announces The Appointment Of Kamil Isaev To Its Board Of Directors And Joseph Scheffler As Interim Chief Financial Officer
IPAImmunoPrecise To Transfer To Nasdaq Capital Market On Feb. 21
IPAImmunoPrecise Antibodies CEO Jennifer Bath And BioStrand Co-Founders Dirk Van Hyfte And Ingrid Brands Collectively Acquired A Total Of 763,120 Shares Of IPA On The Open Market For An Aggregate Amount Of $306,000
IPAImmunoPrecise Antibodies Q1 Sales $4.70M Beat $4.02M Estimate
IPA